Medical Dissertation, Data collection and management 
“Evaluating 50 hospitalized Children with Nephroblastoma”
Tehran Children hospital, Iran
Research Investigator
 “Surveillance and management of lymphoma with serial FDG PET-CT” 
University of Southern California, Department of Radiology and nuclear Medicine (refer to publication )   2006-2007
Principal Investigator
Principal Investigator
Trial to Assess Chelation Therapy
National Institute of Health (NIH)
Data collection for submission as best case series in complimentary and alternative medicine
Office of Cancer Complementary and Alternative Medicine
National Cancer Institute ( NCI)
Co author
Botanical and Mycological Medicine in Integrative Oncology 
Integrative Oncology (Weil Integrative Medicine Textbook), Donald Abrams, Andrew Weil, 2013

Speaker and Medical consultant 
Caris Life Sciences ( Caris Oncology Laboratory) 
Peer review expert
Journal of Cancer Therapy ( JCT) 
British Journal of Medicine and Medical Research. ( BJM)
Journal of cancer and tumor international
Editorial Board
Cancer Studies

1. M.A Nezami,M.D., Mirshemirani, M., M D
 “Retrospective study of 50 Hospitalized children with Nephroblastoma/ Wilm’s Tumor”
Clinical research, medical dissertation, April 1996

2. Davidson, G.C., Collins, L., Nezami, M.A. & Dequattro, V.L. 
“Psychological correlates of heart’s structural variation.”
Poster presented at the society of behavioral science meeting, San Diego, California 1993

3. Nezami E., Davison, GC, Nezami, M.A. & Collins L.
“Hostility in relation to cardiovascular reactivity”
University of Southern California, Paper published in International Journal of Psychology, and presented in 26th international congress of psychology, Montreal, Canada, p. 127, 1996

4. Jadvar H, Xu A, Tumeh P, Pollock J, Nezami M.A., Conti PS
 " Surveillance and management of  lymphoma with serial FDG PET-CT", 
Proc RSNA 91st Scientific Assembly & Ann Meeting, Chicago, IL, p. 673; 2005

5.  M. A. Nezami, M.D, Victoria Kubal MS, BCBA, John Monteleone M.D., MPH Davin Young Clarke  M.A., “Effects of Exercise Prescription and Nutrition Counseling on Patients at Risk for Cardiovascular Disease”Invited presenter, 3rd annual colloquium 
University of California, San Francisco, (UCSF), 2007

6. J. Monteleone, MD, MPH, M.A. Nezami M.D., Mimi-Mott Smith FNP-MPH
“Changing Behavior using personalized exercise and nutrition prescriptions for patients at cardiovascular risk”
Society of Teachers in Family Medicine (STFM), 16th annual meeting, published STFM 16th annual journal, p 63, Chicago, 2007

7. M. Nezami, MD
” Improved symptoms of multiple sclerosis in response to nutritional therapy: an integrative approach to neurodegenerative disorders, a case report”
Integrative Medicine, A Clinician’s Journal ( IMCJ), Sept, 2011

8. M. Nezami MD
Tumor board presentation "Breast cancer complete remission using combination therapy, chemotherapy with epigenetic treatments, A case report" March, 2012, CRMC, Clovis, California

9. M. Nezami MD
 MultiTargeted Epigenetic therapies, MTET
Invited presenter and candidate for partnership opportunities
Lymphoma and Leukemia Society (LLS), San Francisco, 2012

10. M.Nezami MD, S.Hager DO, D. Stobbe MD, 
Multitargeted Epigenetic Therapy ( MTET) and it's rationale in an integrative approach
Institute for Research ( IRB) in Bio medicine, Barcelona International Conference on Epigenetics and Cancer, Barcelona, Spain, November, 2013

11. M.Nezami MD, S.Hager DO, D. Stobbe MD
Multitargeted Epigenetic Therapy ( MTET) 
Molecular Med Tri-conference,( ex, human genome project and sequencing), February 10-12, 2014, San Francisco, CA

12. M.Nezami MD, S Hager, Do
"Surrogate markers of survival , a case review for an antiangiogenic therapy in cancer" 
Pancreatic Cancer Innovations in research and treatment
American Association for Cancer Research ( AARC), May 18-21, 2014 New Orleans, Louisiana

13. M.Nezami MD, S Hager, Do, A. Gouldsimon MD
"Surrogate Markers for survival, a case review for an antiangiogenic therapy in cancer"
World Pharmaceutical Congress, Trackling Translational Challenges, May 21-23, 2014, Boston, Massachusetts

14. M.Nezami MD, Steve Hager DO, A. Gouldsimon MD
"Surrogate Markers of survival, a case review for an antiangiogenic therapy in cancer"
World Molecular Imaging Society and World Molecular Imaging Congress( WMIC) 
Korea, September 2014

Weil's Integrative Oncology Textbook, second edition, 
Botanical and Mycological Medicine in Integrative Oncology 
Integrative Oncology, Donald Abrams, Andrew Weil, Sep 2014

16. M.Nezami MD, Aron Gould Simon MD,
" Biological translational tools to predict clinical outcome in advanced cancer” 
Molecular Med Tri-cone 2015, San Francisco, February 2015( human genome project and sequencing)

17. M. Nezami MD, J. Garner, Aron Gouldsimon, MD, 
"Epigenetic regulation of angiogenesis", A review of 100 cases of advanced cancer"
Translational epigenetics,  Festival of Genomics, Boston, June 23, 2015

18. M. Nezami MD, Daniel Stobe MD, Aron Gouldsimon, MD
"Translational epigenetics in lung cancer, A case review of multitargeted epigenetic therapy ( MTET)", 
16th annual international lung cancer congress, Huntington Beach, CA July, 2015 

19. Nezami MA, Gouldsimon A
" Heterogenous Approach for Heterogenous disease, Heterogeneity in cancer genomics and epigenetic approach", Cancer Science, vol 1,1, August 2015

20. M.Nezami MD, " Epigenetic regulation of hypoxia, Genomic Bioinformatics", 
Europe Society of Bio Banking ( ESBB), London, Oct 1st, 2015

21. M. Nezami MD
"Biological interventions to interfere microenvironmental seduction by tumor cells"
Symposia on Cancer Research, Emerging concepts in host response to cancer, MD Anderson Cancer center, Houston, TX, October 8-9, 2015

22. M.Nezami MD, Steve Hager DO
" Prognostic surrogate makers for survival in pancreatic cancer, a case series for a novel antiangiogenic therapy( Multitargeted epigenetic therapy( MTET)  
French Association for Pancreatic Cancer Research ( AFRCP), Pancreatic Cancer Symposium, Marcielle, France, October 28-30

23. M. Nezami MD, Steve Hager DO, Richard Lanman MD
" Impact of Multitargeted Epigenetic therapy ( MTET), a series of 100 consecutive advanced solid tumor cancers"
AACR- NCI EORTC Molecular Targets and Cancer Therapeutics Conference, Nov 5-9, 2015, Boston, Massachusetts

24. M. Nezami MD, Steve Hager DO
“Heterogenous approach for heterogenous disease, heterogeneity in cancer genomics and epigenetic approach”
AACR- NCI EORTC Molecular Targets and Cancer Therapeutics Conference, Nov 5-9, 2015, Boston, Massachusetts

25. M.Nezami MD, Aron Gouldsimon MD
" Application of multitargeted Epigenetic therapy and review of case series in recurrent advanced Non small Cell Lung Cancer, Heterogenous approach for heterogenous disease, Heterogeneity in cancer genomics and epigenetic approach"
Cancer Science, open access, scient online, Vol. 1,  http://scientonline.org/open-access/heterogenous-approach-for-heterogenous-disease-heterogeneity-in-cancer-genomics-and-epigenetic-approach.pdf

26. M. Nezami MD, Jessica garner PA, Megan Elam
" Epigenetic therapies, Immune therapies and Anti angiogenic therapies, The Triad of Oncology"
Angiogenesis, The cause or effect?"
Journal of Precision Medicine, November 2015, Page 43

27. M. Nezami MD, Steve Hager DO, Jessica Garner PA,
" Epigenetic Regulation of heterogeneity in solid tumors, A case series for a novel epigenetic therapy"
Society of Integrative Oncology ( SIO), Integrative Innovations, Nov 12-14, 2015, Boston, Massachusetts

28. M.Nezami MD, Daniel Stobe MD, Aron Gould Simon MD
"Prognostic surrogate markers for survival, a case series for a novel antiangiogenic therapy( Multitargeted Epigenetic Therapies/ MTET)" Abstract 73
Society of Integrative Oncology( SIO), November 14-16, 2015, Boston, Massachusetts

29. M. Nezami MD
" Epigenetic regulation of hypoxia and heterogeneity in cancer"8th Euro Global Summit on Cancer Therapy, November 3th-5th, 2015, Valencia, Spain

30. M. Nezami MD
" Multitargeted Epigenetic therapy and it's application in a case series of Gastric Cancer"
2nd International Gastrointestinal Cancer Congress ( IGCC), October 14-16th, Shahid Beheshti University, Comprehensive Cancer Center, Tehran, Iran

31. Nezami M, Hager S, Garner, J
" Epidermomesenchymal (Transition( EMT) and Anti EMT Strategies in Cancer", Journal of Cancer therapy  (JCT), Vol 6, No 11, November 2015, Paper ID: 890225

32. M.Nezami MD
"Epigenetic regulation of Hypoxia, a case series for multitargeted epigenetic therapy"4th Cancer Epigenetic Conference, Global Technology Community ( GTC), November 16-17th, San Francisco, CA

33. M.Nezami MD, A Gouldsimon, D. Stobe 
" Epigenetic regulation of Hypoxia and heterogeneity", ESMO Journal , Annals of Oncology, Submission ID:#495ESMO
Asia 2015 Congress, December 18-21, Singapore

34. M. Nezami MD
“Chemoprevention and epigenetic multitargeted approach” , 2016 Cancer survivorship Symposium: Advancing Care and Research, Abstract Submission ID:156951 (Abstract Number for Online Publication: e297)

35.M. Nezami MD, Aroun Gouldsimon MD, Jessica Garner
 "Correlation of an EX VIVO model with clinical application of an epigenetic modifier, inhibiting tumor growth and metastasis, in resistant cholangiocarcinoma - A case study" ,
 Journal of Cancer Therapy, Vol 7, No.1, Jan 2016

36. M.Nezami MD
"Chemoprevention and Epigenetic Multitargeted Approach"
Dana-Farber Cancer Institute, Cancer Survivorship Symposium: Advancing Care and Research
Journal of Clinical Oncology 34, 2016 ( Suppl 3S, Abstr e297)

37. M.Nezami MD 
"Multitargeted Epigenetic therapy and it's application in a case series of advanced Gastric Cancer"
The 2nd International Conference on Oncology and Therapy (COT 2016)  
March 2 - 4, 2016 in Beijing, China. 

38. M. Nezami MD, Aroun GouldSimon MD
"Biological interventions to interfere microenvironmental seduction by tumor cells, a breakthrough strategy in clinical oncology to inhibit angiogenesis and metastasis"
Molecular Medicine TRI-CON 2016 , March 6 -11, 2016, San Francisco, CA

39.M.A.Nezami MD, Steve Hager Do, Jessica Garner PA
" Preliminary Findings on Multi-Targeted Epigenetic Therapy in Modifying Telomerase Activity"
Journal of Cancer Science( Scient Open Access Journal), March 16, 2016

40. M.Nezami MD
" Invitro and invivo proof of concept for an effective antineoplastic combination of novel anti HIF therapy in pancreatic cancer"
American Association for Cancer Research ( AACR), Pancreatic Cancer, Advances in Science and Clinical Care
May 12-15, Orlando, Florida

41. M.Nezami MD, S. Hager, DO J. Garner
"The Role of Telomeres in Cancer Development and Progression, and the Double Edge Sword Effect with Tamoxifen"
Biology and Medicine ( Biol Med 2016, 8:3)

42. M. Nezami MD, Steven Hager DO, Jessica Garner
"Preliminary Findings on Multi-Targeted Epigenetic Therapy (MTET) in Modifying Telomerase Activity" 
- Cancer Science; Open Access, Scient access, published March, 2016

43. M. Nezami MD, Steven Hager DO, Jessica Garner
"Epigenetic Tumor Response to Hypoxia: An Epimutation Pattern and a Method of Multi-Targeted Epigenetic Therapy (MTET)" - Journal of Cancer Therapy, Vol 7, No 4, Apr 13, 2016, DOI: 10.4236/jct.2016.74027 

44. M. Nezami MD
Peer review expert, British Journal of Medicine and Medical Research 
" Tumor markers in head and neck neoplasm: an overview"
Published: Ms_BjMMR_24998

45. Peer review expert, Science Domain International, Asian Journal of Medicine and Health
" Superficial Angiomyxoma of right gluteal region- A rare case report"

46. Peer review expert, Science Domain International,Journal of Advances in Medical and Pharmaceutical Sciences
" Effect of Hypoxia-inducible factor-1 and 2 on tumor growth"

47. Peer review expert, Science Domain, Journal of cancer and tumor international," The interest of serum alkaline phosphatase in the confirmation of diagnosis for tumors in children and adolescents" Ms_JCTI_2993

48. Peer Review Expert, Biology and Medicine, Medical Sciences 17-134
"Association between serum Trans fatty acids concentrations and leucocyte telomere length in US adults" Feb, 2017

49. Peer review expert, Biology and Medicine, Medical Sciences 17-285
" Long Non-coding RNA Biomarker for Human Laryngeal Squamous Cell Carcinoma Prognosis", March 2017

50. M.Nezami MD
"Epigenetic regulation of hypoxia: Modifying metastasis by regulating epigenome- A Case review of multi targeted epigenetic therapy (MTET) and its application in Stage IV Renal Cell Carcinoma
( submitted to) International Conference on Oncology and Radiology( ICOR), Dubai, UAE
October 27-29, 2016

51. M.Nezami MD
( Key note speaker and organizing committee member)
"Epigenetic therapies and the use of multitargeted approach, a new concept in cancer therapeutics"
Journal of Cancer Science and Therapy, 
14th world anti cancer therapy convention
Dubai, UAE, Nov 21-22, 2016

52. M.Nezami MD
" Biological interventions to interfere microenvironmental and endocrine machinery in cancer" Application of endocrine manipulation in advanced cancer
 Journal of Cancer Science and Therapy, November 21-23, 2016,

53. M. Nezami MD, "Multi targeted Epigenetic therapy and hypoxia response elements, A turning point in radiation oncology"  
2nd International conference on Nuclear Medicine and Radiation Therapy, July 27-28, 2017, Rome, Italy

54. M.Nezami MD
" Biological modulation of PARP inhibition in triple negative breast cancer: A case report of combinational approach implementing histone deacetylase inhibition with PARP inhibition in advanced breast cancer", 2017 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference, October 26-30, 2017 in Philadelphia, Pennsylvania

55. M.Nezami MD, Jessica Garner
"Role of antiangiogenic therapy in prevention of recurrence in hormonal positive breast cancer, a secondary prevention strategy and method of therapy", Journal of Cancer therapy, 6.2017, 8/546.552

56: Landscape of BRCA1 and BRCA2 germline, somatic, and reversion alterations detectable by cell-free DNA testing among patients with metastatic breast, ovarian, pancreatic, or prostate cancerLandscape of BRCA1 and BRCA2 germline, somatic, and reversion alterations detectable by cell-free DNA testing among patients with metastatic breast, ovarian, pancreatic, or prostate cancer

Aditya Bardia1, Thereasa A. Rich, Victoria M. Raymond, .....Mohammad Amin Nezami, Sandip Patel, Benedito A. Carneiro, Grace Wang, Alice C. Fan

ASCO 2018

M. Nezami MD.

Dr. Nezami is graduated from USC and UCSF residencies. He has functioned as a faculty teacher during his training as well as invited presenter at society of teachers in Family medicine.He has been in practice for 18 years and currently is the president of Medical Centers of Hope in California.

Dr Nezami also serves as researcher and national and international speaker, in oncology and epigenetic field.  He has been involved in many research projects and publications, presentations including integrative medicine, Epigenetic therapies (2013 Barcelona Conference on Epigenetics and Cancer, American Association for Cancer Research, Molecular med Tricone and World pharma Congress) author, Integrative Medicine, A Clinician Journal, as well as investigator in conventional oncology literature. (Surveillance in lymphoma, published 2006). He is a co author of Weil’s textbook for integrative oncology. (2014)

 Dr. Nezami is an inventor and innovator and has designed new method of treating advanced cancer, called Modified Multi Molecular Targeted Epigenetic Therapy (MTET). With this method, during the last 7 years, he has successfully treated many patients, mostly with advanced stage four cancer who had failed all other conventional methods. Several cancer institutions, including MD Anderson cancer center and private oncology centers have already started investigating his method in either preclinical or clinical settings, showing extra ordinary results Dr. Nezami has served as principal investigator by NIH, National Institute of Health; and he has been involved with National cancer institute (NCI) in the best case series. His main areas of interest are Integrative oncology and immunology. He currently consults and trains other physicians in both epigenetic therapies, as well as integrative oncology, and is extensively involved in research and pursuing clinical trials in this field.

CALL US ( 949) 515 4673
Precision Medicine in oncology


Dr Christopher Duma is a board certified neurosurgeon specialist serving as chief medical officer in neurooncology division at Sahel oncology LLC. He serves as medical director of Brain and Spine Surgeons of OC and Medical director of the Brain Tumor program at Hoag Memorial HospitalPresbyterian in Newport Beach, california. He also serves as assistant clinical professor of neurosurgery at the University of California, Irvine school of medicine as well as director of radiosurgery for UCI medical centers's department of Neurosurgery residency training program. His affiliations include Mission Hospital in Laguna Beach,  UCI medical center in Orange county,and Orange Coast memorial medical center in Fountain valley. 

B i o g r a p h y

Christopher Duma MD FACS 

​Dr Duma received his general neurosurgical training at George Town university Hospital in Washington, D.C., followed by a fellowship at the University of Pittsburgh Medical Center Presbyterian in Gamma Knife radiosurgery and stereotactic and functional neurosurgery. He has been involved in medical research since his undergraduate education, beginning at the Cornell University School of Medicine’s Department of Neuropharmacology and continuing on through his graduate years at Memorial Sloan-Kettering Cancer Center’s Department of Neurology Pain Service. In 2002, Dr. Duma founded The Foundation for Neurosciences, Stroke and Recovery to provide outreach and assistance to patients with movement disorders. He continues to serve as Chair of the Foundation for Neurosciences, Stroke and Recovery, and remains active in Orange County’s medical community.

His general neurosurgery is performed using state-of-the art neuronavigational computers and he prides himself in being a master of minimally invasive neurosurgery accomplishing better results, by being less invasive and using more powerful, modern tools.Dr. Christopher  Duma is one of the most experienced in his field. In addition, he has been at the forefront of research in immunotherapy for primary brain gliomas such as glioblastoma multiforme, anaplastic astrocytoma, and astrocytomas and is involved with futuristic research in the use of immunotherapy to fight malignant brain tumors. Dr Duma is also interested in combination of his “leading edge Gamma knife techniques” with other modalities of antineoplastic therapies including epigenetic therapy( MTET).